Conflict of interest: Nothing to declare.
Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program
Version of Record online: 20 FEB 2014
© 2014 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Volume 61, Issue 8, pages 1486–1489, August 2014
How to Cite
Kang, M. H., Reynolds, C. P., Maris, J. M., Gorlick, R., Kolb, E. A., Lock, R., Carol, H., Keir, S. T., Wu, J., Lyalin, D., Kurmasheva, R. T., Houghton, P. J. and Smith, M. A. (2014), Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. Pediatr. Blood Cancer, 61: 1486–1489. doi: 10.1002/pbc.24989
- Issue online: 10 JUN 2014
- Version of Record online: 20 FEB 2014
- Manuscript Accepted: 21 JAN 2014
- Manuscript Received: 18 NOV 2013
- National Cancer Institute. Grant Numbers: NO1-CM-42216, NO1-CM91001-03, CA21765, CA108786
Additional Supporting Information may be found in the online version of this article at the publisher's web-site.
|pbc24989-sm-0001-SuppFig-S1.tif||2237K||Fig. S1. Pharmacodynamic evaluation.|
|pbc24989-sm-0002-SuppTab-S1.docx||153K||Table SI. Efficacy MLN0128 Against PPTP Xenograft Models.|
|pbc24989-sm-0002-SuppData-S1.doc||77K||Supplemental Response Definitions|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.